Grifois, S.A. (GRFS) is a publicly traded Healthcare sector company. As of May 21, 2026, GRFS trades at $8.20 with a market cap of $5.36B and a P/E ratio of 0.00. GRFS moved +4.46% today. Year to date, GRFS is -12.12%; over the trailing twelve months it is +1.87%. Its 52-week range spans $6.19 to $11.14. Rallies surfaces GRFS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Grifols drops as Q1 profit rises, dividend plan and guidance reiterated: Grifols reported Q1 2026 results today, posting net profit of €73 million (+21.9% YoY) on €1.7 billion of revenue and confirming its 2026 outlook. It also said it expects shareholders to approve a final cash dividend charged to 2025 and reiterated it is evaluating a potential IPO of its U.S. Biopharma business.
| Metric | Value |
|---|---|
| Price | $8.20 |
| Market Cap | $5.36B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.16% |
| 52-Week High | $11.14 |
| 52-Week Low | $6.19 |
| Volume | 4 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
GRFS analyst coverage data. Average price target: $0.00.